Equities

Simcere Pharmaceutical Group Ltd

Simcere Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.61
  • Today's Change0.08 / 1.45%
  • Shares traded3.11m
  • 1 Year change-25.79%
  • Beta0.3527
Data delayed at least 15 minutes, as of Jul 05 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.

  • Revenue in HKD (TTM)7.10bn
  • Net income in HKD767.83m
  • Incorporated2015
  • Employees7.03k
  • Location
    Simcere Pharmaceutical Group LtdNo. 699-18, Xuanwu Road, Xuanwu DistrictNANJING ChinaCHN
  • Websitehttp://www.simcere.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Yichang Hec Changjiang Pharmactcl Co Ltd6.76bn2.14bn7.88bn4.62k3.680.92493.271.172.432.437.689.690.51113.624.091,464,263.0015.078.0324.4611.8179.2179.9729.4820.801.3011.160.247515.8168.0820.182,501.2416.15-11.50--
AIM Vaccine Co Ltd1.28bn-1.40bn8.26bn1.62k--2.11--6.47-1.15-1.151.053.23------785,492.10--------75.88---164.24--0.7583-14.040.3158---6.06---307.07------
Luye Pharma Group Ltd6.60bn572.15m10.61bn5.27k18.450.7887.961.610.15290.15291.773.580.2472.423.601,252,222.002.172.803.564.4568.4470.538.7810.391.213.100.393111.822.703.50-11.94-16.39-14.05--
SciClone Pharmaceuticals (Holdings) Ltd3.39bn1.21bn11.80bn1.05k10.113.228.673.481.851.855.215.810.75853.563.833,228,498.0026.9727.0933.3436.3274.6776.0635.5535.434.5033.700.0122.9814.7617.5031.1615.9625.65--
Shanghai Henlius Biotech Inc5.80bn586.56m12.42bn3.64k21.235.2712.772.141.081.0810.624.330.57311.959.101,593,481.005.80-8.5912.47-14.1472.6471.7710.12-27.370.37866.480.6512--67.82273.51178.53--49.14--
SSY Group Ltd6.46bn1.32bn12.65bn5.60k9.621.827.231.960.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
Zai Lab Ltd2.27bn-2.65bn13.17bn2.18k--2.16--5.79-2.73-2.732.356.120.26972.845.61---31.41-37.72-36.81-42.7262.8664.75-116.45-282.444.43--0.0596--24.03360.0324.51---3.45--
Simcere Pharmaceutical Group Ltd7.10bn767.83m14.07bn7.03k19.201.8612.791.980.2880.2882.722.970.61063.532.651,010,167.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
The United Laboratories Intl. Hldgs Ltd.14.76bn2.90bn15.06bn15.00k5.191.104.291.021.601.608.127.530.68713.366.15984,005.6013.517.8920.5212.6446.1144.1719.6612.731.74--0.105528.9921.2212.8470.8531.6624.1946.04
3SBio Inc8.40bn1.66bn15.19bn5.41k9.451.017.361.810.67080.67083.446.290.34261.587.011,551,706.006.957.449.039.2984.9882.9120.3021.502.2622.720.2266--13.8411.26-19.133.948.78--
China Medical System Holdings Ltd8.61bn2.58bn15.98bn5.70k6.230.96335.691.861.051.053.516.800.45173.426.191,509,960.0013.4418.4415.7021.1476.2475.4729.7634.263.98--0.077240.14-12.438.08-26.335.3538.695.19
Grand Pharmaceutical Group Ltd10.53bn1.88bn16.79bn10.53k8.831.097.341.590.53560.53563.004.330.46922.9410.26999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981922.960.183126.9410.1212.06-9.5921.415.6924.77
China Traditional Chinese Med Hldg CoLtd19.47bn1.38bn18.48bn17.30k13.390.8136.880.94940.27420.27423.874.510.49851.472.161,125,090.003.844.605.857.0751.1857.077.709.771.489.830.177317.3526.699.9968.11-2.24-12.75--
WuXi XDC Cayman Inc2.28bn304.59m19.10bn1.18k57.263.2651.888.370.27840.27842.124.89------1,936,789.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
Data as of Jul 05 2024. Currency figures normalised to Simcere Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.53%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 202324.51m0.94%
Principal Global Investors (Hong Kong) Ltd.as of 31 Dec 202318.91m0.72%
The Vanguard Group, Inc.as of 06 Jun 202418.70m0.72%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 202316.86m0.65%
GF Fund Management Co., Ltd.as of 31 Dec 202313.73m0.53%
China Asset Management Co., Ltd.as of 31 Dec 202312.34m0.47%
Dimensional Fund Advisors LPas of 06 Jun 202411.96m0.46%
Essence Fund Co., Ltd.as of 31 Dec 202311.25m0.43%
BlackRock Fund Advisorsas of 06 Jun 20248.17m0.31%
HSBC Jintrust Fund Management Co. Ltd.as of 31 Dec 20237.82m0.30%
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.